Shanghai RAAS Blood Products Co Ltd Class A (002252) — Strategic Asset Allocation Index
Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Strategic Asset Allocation Index of 4.4% as of September 2023. Strategic assets (PP&E of CN¥1.32 Billion plus long-term investments of CN¥-) total CN¥1.32 Billion, measured against net assets of CN¥29.82 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Shanghai RAAS Blood Products Co Ltd Class A Strategic Asset Allocation Index (2005–2022)
This chart shows how Shanghai RAAS Blood Products Co Ltd Class A's Strategic Asset Allocation Index has evolved across 18 annual periods from 2005 to 2022. As of September 2023, the index stands at 4.4%, representing strategic assets of CN¥1.32 Billion against net assets of CN¥29.82 Billion CNY. Explore 002252 cash flow metrics to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Shanghai RAAS Blood Products Co Ltd Class A (2005–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2022, covering 18 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Shanghai RAAS Blood Products Co Ltd Clas.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 4.4% | CN¥1.28 Billion | CN¥1.28 Billion | CN¥- | CN¥28.81 Billion | ▼ -0.5 pp |
| 2021 | 4.9% | CN¥1.28 Billion | CN¥1.28 Billion | CN¥- | CN¥25.90 Billion | ▲ +0.0 pp |
| 2020 | 4.9% | CN¥1.23 Billion | CN¥1.23 Billion | CN¥- | CN¥25.13 Billion | ▼ -5.0 pp |
| 2019 | 9.9% | CN¥1.14 Billion | CN¥1.14 Billion | CN¥- | CN¥11.49 Billion | ▼ -0.4 pp |
| 2018 | 10.3% | CN¥1.13 Billion | CN¥1.13 Billion | CN¥- | CN¥10.90 Billion | ▲ +1.4 pp |
| 2017 | 8.9% | CN¥1.12 Billion | CN¥1.12 Billion | CN¥- | CN¥12.48 Billion | ▼ -1.0 pp |
| 2016 | 10.0% | CN¥1.17 Billion | CN¥1.17 Billion | CN¥- | CN¥11.73 Billion | ▲ +0.0 pp |
| 2015 | 10.0% | CN¥1.07 Billion | CN¥1.07 Billion | CN¥- | CN¥10.71 Billion | ▼ -2.3 pp |
| 2014 | 12.2% | CN¥1.06 Billion | CN¥1.06 Billion | CN¥- | CN¥8.62 Billion | ▼ -43.9 pp |
| 2013 | 56.1% | CN¥618.43 Million | CN¥618.43 Million | CN¥- | CN¥1.10 Billion | ▲ +2.1 pp |
| 2012 | 54.0% | CN¥550.93 Million | CN¥550.93 Million | CN¥- | CN¥1.02 Billion | ▲ +11.9 pp |
| 2011 | 42.2% | CN¥391.22 Million | CN¥391.22 Million | CN¥- | CN¥927.27 Million | ▲ +12.0 pp |
| 2010 | 30.2% | CN¥251.34 Million | CN¥251.34 Million | CN¥- | CN¥831.21 Million | ▲ +9.9 pp |
| 2009 | 20.3% | CN¥154.89 Million | CN¥154.89 Million | CN¥- | CN¥763.33 Million | ▲ +5.7 pp |
| 2008 | 14.6% | CN¥110.39 Million | CN¥110.39 Million | CN¥- | CN¥754.76 Million | ▼ -45.4 pp |
| 2007 | 60.0% | CN¥102.02 Million | CN¥102.02 Million | CN¥- | CN¥170.01 Million | ▲ +1.5 pp |
| 2006 | 58.5% | CN¥91.78 Million | CN¥91.78 Million | CN¥- | CN¥156.77 Million | ▲ +21.8 pp |
| 2005 | 36.7% | CN¥85.06 Million | CN¥85.06 Million | CN¥- | CN¥231.70 Million | — |